|
|
| Line 1: |
Line 1: |
| __NOTOC__ | | __NOTOC__ |
| | {{CMG}}; {{AE}} {{SS}} |
|
| |
|
| {{Dabigatran}}
| | ==[[Dabigatran Etexilate Mesylate|Dabigatran Etexilate Mesylate]]== |
| {{CMG}}; {{AE}} {{SS}}
| |
|
| |
|
| '''''For patient information, click [[XXXXX (patient information)|here]]'''''
| | * [[Pradaxa|Pradaxa]] |
|
| |
|
| ==Overview== | | ==Overview== |
| Line 13: |
Line 13: |
|
| |
|
| Anticoagulants:Direct thrombin (II) inhibitors | | Anticoagulants:Direct thrombin (II) inhibitors |
|
| |
| ==US Brand Names==
| |
|
| |
| PRADAXA<sup>®</sup>
| |
|
| |
| ==FDA Package Insert==
| |
|
| |
| '''| [[Dabigatran indications and usage|Indications and Usage]]'''
| |
| '''| [[Dabigatran dosage and administration|Dosage and Administration]]'''
| |
| '''| [[Dabigatran dosage forms and strengths|Dosage Forms and Strengths]]'''
| |
| '''| [[Dabigatran contraindications|Contraindications]]'''
| |
| '''| [[Dabigatran warnings and precautions|Warnings and Precautions]]'''
| |
| '''| [[Dabigatran adverse reactions|Adverse Reactions]]'''
| |
| '''| [[Dabigatran drug interactions|Drug Interactions]]'''
| |
| '''| [[Dabigatran use in specific populations|Use in Specific Populations]]'''
| |
| '''| [[Dabigatran overdosage|Overdosage]]'''
| |
| '''| [[Dabigatran description|Description]]'''
| |
| '''| [[Dabigatran clinical pharmacology|Clinical Pharmacology]]'''
| |
| '''| [[Dabigatran nonclinical toxicology|Nonclinical Toxicology]]'''
| |
| '''| [[Dabigatran clinical studies|Clinical Studies]]'''
| |
| '''| [[Dabigatran how supplied storage and handling|How Supplied/Storage and Handling]]'''
| |
| '''| [[Dabigatran patient counseling information|Patient Counseling Information]]'''
| |
| '''| [[Dabigatran labels and packages|Labels and Packages]]'''
| |
|
| |
| ==Mechanism of Action==
| |
| Dabigatran and its acyl glucuronides are competitive, direct thrombin inhibitors. Because thrombin (serine protease) enables the conversion of fibrinogen into fibrin during the coagulation cascade, its inhibition prevents the development of a thrombus. Both free and clot-bound thrombin, and thrombin-induced platelet aggregation are inhibited by the active moieties.
| |
|
| |
| ==References==
| |
|
| |
| {{Reflist|2}}
| |
|
| |
|
|
| |
|
| [[Category:Direct thrombin (II) inhibitors]]
| | {{Antithrombotics}} |
| [[Category:Anticoagulants]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| {{WikiDoc Help Menu}} | |
| {{WikiDoc Sources}}
| |